Evidence map›Paper›PMID 27647909›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2016

Whole-exome sequencing identifies multiple loss-of-function mutations of NF-κB pathway regulators in nasopharyngeal carcinoma.

Hong Zheng, Wei Dai, Arthur Kwok Leung Cheung, Josephine Mun Yee Ko, Rebecca Kan, Bonnie Wing Yan Wong, Merrin Man Long Leong, Mingdan Deng, Tommy Chin Tung Kwok, Jimmy Yu-Wai Chan and 13 more

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 2 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 2 syntheses or guidelines pooled it, 189 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  6. Molecular and Immune Landscape of Recurrent and/or Distant Metastatic Squamous Cell Carcinoma of the Head and Neck: An EORTC/IMMUCAN Project.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 2 countries.

Hong ZhengDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, People's Republic of China.
Wei DaiDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, People's Republic of China.
Arthur Kwok Leung CheungDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, People's Republic of China.
Josephine Mun Yee KoDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, People's Republic of China.
Rebecca KanDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, People's Republic of China.
Bonnie Wing Yan WongDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, People's Republic of China.
Merrin Man Long LeongDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, People's Republic of China.
Mingdan DengDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, People's Republic of China.
Tommy Chin Tung KwokDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, People's Republic of China.
Jimmy Yu-Wai ChanCenter for Nasopharyngeal Carcinoma Research, The University of Hong Kong, Hong Kong, People's Republic of China; Department of Surgery, The University of Hong Kong, Hong Kong, People's Republic of China.
Dora Lai-Wan KwongDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, People's Republic of China; Center for Nasopharyngeal Carcinoma Research, The University of Hong Kong, Hong Kong, People's Republic of China.
Anne Wing-Mui LeeDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, People's Republic of China; Center for Nasopharyngeal Carcinoma Research, The University of Hong Kong, Hong Kong, People's Republic of China.
Wai Tong NgCenter for Nasopharyngeal Carcinoma Research, The University of Hong Kong, Hong Kong, People's Republic of China; Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, People's Republic of China.
Roger Kai Cheong NganCenter for Nasopharyngeal Carcinoma Research, The University of Hong Kong, Hong Kong, People's Republic of China; Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, People's Republic of China.
Chun Chung YauCenter for Nasopharyngeal Carcinoma Research, The University of Hong Kong, Hong Kong, People's Republic of China; Department of Oncology, Princess Margaret Hospital, Hong Kong, People's Republic of China.
Stewart TungCenter for Nasopharyngeal Carcinoma Research, The University of Hong Kong, Hong Kong, People's Republic of China; Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, People's Republic of China.
Victor Ho-Fun LeeDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, People's Republic of China; Center for Nasopharyngeal Carcinoma Research, The University of Hong Kong, Hong Kong, People's Republic of China.
Ka-On LamDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, People's Republic of China; Center for Nasopharyngeal Carcinoma Research, The University of Hong Kong, Hong Kong, People's Republic of China.
Chung Kong KwanCenter for Nasopharyngeal Carcinoma Research, The University of Hong Kong, Hong Kong, People's Republic of China; Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, People's Republic of China.
Wing Sum LiCenter for Nasopharyngeal Carcinoma Research, The University of Hong Kong, Hong Kong, People's Republic of China; Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, People's Republic of China.
Stephen YauDepartment of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, People's Republic of China.
Kwok-Wah ChanDepartment of Pathology, The University of Hong Kong, Hong Kong, People's Republic of China.
Maria Li LungDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, People's Republic of China; Center for Nasopharyngeal Carcinoma Research, The University of Hong Kong, Hong Kong, People's Republic of China; mlilung@hku.hk.
University of Hong Kong · HKChinese University of Hong Kong · CNQueen Elizabeth Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nasopharyngeal carcinoma (NPC) is an epithelial malignancy with a unique geographical distribution. The genomic abnormalities leading to NPC pathogenesis remain unclear. In total, 135 NPC tumors were examined to characterize the mutational landscape using whole-exome sequencing and targeted resequencing. An APOBEC cytidine deaminase mutagenesis signature was revealed in the somatic mutations. Noticeably, multiple loss-of-function mutations were identified in several NF-κB signaling negative regulators NFKBIA, CYLD, and TNFAIP3 Functional studies confirmed that inhibition of NFKBIA had a significant impact on NF-κB activity and NPC cell growth. The identified loss-of-function mutations in NFKBIA leading to protein truncation contributed to the altered NF-κB activity, which is critical for NPC tumorigenesis. In addition, somatic mutations were found in several cancer-relevant pathways, including cell cycle-phase transition, cell death, EBV infection, and viral carcinogenesis. These data provide an enhanced road map for understanding the molecular basis underlying NPC.

Indexed as

CarcinomaCell Line, TumorExome SequencingGene Knockdown TechniquesHumansLoss of Function MutationMutation RateNasopharyngeal CarcinomaNasopharyngeal NeoplasmsNF-kappa BNF-KappaB Inhibitor alphaSignal TransductionNF-kappa BNF-KappaB Inhibitor alphaNFKBIA protein, humanAPOBEC-mediated signaturenasopharyngeal carcinomaNF-κB signalingsomatic mutation landscapewhole-exome sequencing

Identifiers

PMID27647909
PMCPMC5056105
OpenAlexW2522155417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.